DOCSLIB.ORG

AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small Cell Lung Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small Cell Lung Cancer Author Manuscript Published OnlineFirst on November 17, 2020; DOI: 10.1158/1078-0432.CCR-20-2845 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Research Article AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small Cell Lung Cancer Michael J. Giffin,1* Keegan Cooke,1* Edward K. Lobenhofer,2 Juan Estrada,1 Jinghui Zhan,1 Petra Deegen,3 Melissa Thomas,4 Christopher M. Murawsky,5 Jonathan Werner,2 Siyuan Liu,1 Fei Lee,6 Oliver Homann,7 Matthias Friedrich,3 Joshua T. Pearson,8 Tobias Raum,9 Yajing Yang,1 Sean Caenepeel,1 Jennitte Stevens,10 Pedro J. Beltran,1 Jude Canon,1 Angela Coxon,1 Julie M. Bailis,6 Paul E. Hughes1 1Oncology Research, Amgen Research, Thousand Oaks, CA, USA; 2Translational Safety & Bioanalytical Sciences, Amgen Research, Thousand Oaks, CA, USA; 3Translational Safety & Bioanalytical Sciences, Amgen Research (Munich) GmbH, Munich, Germany; 4Therapeutic Discovery, Amgen Research, South San Francisco, CA; 5Therapeutic Discovery, Amgen Research, Burnaby, BC, Canada; 6Oncology Research, Amgen Research, South San Francisco, CA, USA; 7Genome Analysis Unit, Amgen Research, South San Francisco, CA, USA; 8Pharmacokinetics & Drug Metabolism, Amgen Research, South San Francisco, CA, USA; 9Therapeutic Discovery, Amgen Research (Munich) GmbH, Munich, Germany; 10Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USA *Contributed equally to this work. Current address for Michael J. Giffin is Process Development, Amgen Inc., Thousand Oaks, CA, USA. Current address for Joshua T. Pearson is Pharmacodynamics, Pharmacokinetics, and Drug, Merck Research Labs, South San Francisco, CA, USA. Current address for Pedro J. Beltran is Discovery Biology, UNITY Biotechnology, South San Francisco, CA, USA Correspondence: Paul E. Hughes, Amgen Research, One Amgen Center Drive, Thousand Oaks, CA, USA 91320-1799; Tel: 1-805-447-1137; Email: [email protected]; Julie M. Bailis, Amgen Research, 1120 Veterans Blvd, South San Francisco, CA, USA 94080; Tel: 1-650-244-2361; Email: [email protected] Running title: AMG 757 in Preclinical Models of Small Cell Lung Cancer Keywords: SCLC, AMG 757, BiTE®, orthotopic model, DLL3 Financial support: This work was supported by Amgen Inc. Conflicts of interest: MJG, KC, EKL, JE, JZ, MT, CMM, JW, SL, FL, OH, JTP, YY, SC, JS, PJB, JC, AC, JMB, and PEH are or were employees of and own stock in Amgen Inc. PD, MF, and TR are employees of and own stock in Amgen Research (Munich) GmbH. Word count: 4999 (limit, 5000) 1 Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on November 17, 2020; DOI: 10.1158/1078-0432.CCR-20-2845 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Figures: 6 (limit 6) Supplementary Files: 4 (limit, 8) References: 50 (limit, 50) 2 Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on November 17, 2020; DOI: 10.1158/1078-0432.CCR-20-2845 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 Abstract 2 Purpose: Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with a high 3 relapse rate, limited therapeutic options, and poor prognosis. We investigated the antitumor 4 activity of AMG 757, a half-life extended bispecific T-cell engager molecule targeting delta-like 5 ligand 3 (DLL3) — a target that is selectively expressed in SCLC tumors but with minimal 6 normal tissue expression. 7 Methods: AMG 757 efficacy was evaluated in SCLC cell lines and in orthotopic and patient- 8 derived xenograft (PDX) mouse SCLC models. Following AMG 757 administration, changes in 9 tumor volume, pharmacodynamic changes in tumor-infiltrating T cells (TILs), and the spatial 10 relationship between the appearance of TILs and tumor histology were examined. Tolerability 11 was assessed in nonhuman primates (NHP). 12 Results: AMG 757 showed potent and specific killing of even those SCLC cell lines with very 13 low DLL3 expression (< 1000 molecules per cell). AMG 757 effectively engaged systemically 14 administered human T cells, induced T cell activation, and redirected T cells to lyse tumor cells 15 to promote significant tumor regression and complete responses in PDX models of SCLC and in 16 orthotopic models of established primary lung SCLC and metastatic liver lesions. AMG 757 was 17 well tolerated with no AMG 757-related adverse findings up to the highest tested dose (4.5 18 mg/kg weekly) in NHP. AMG 757 exhibits an extended half-life in NHP which is projected to 19 enable intermittent administration in patients. 20 Conclusions: AMG 757 has a compelling safety and efficacy profile in preclinical studies 21 making it a viable option for targeting DLL3-expressing SCLC tumors in the clinical setting. 22 Abstract word count: 249/250 3 Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on November 17, 2020; DOI: 10.1158/1078-0432.CCR-20-2845 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 Translational Relevance 2 Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy that is associated 3 with a high relapse rate and dismal prognosis. Recent immunotherapeutic approaches using 4 immune checkpoint inhibitors have only modestly improved clinical outcomes. AMG 757 is a 5 first-in-class, half-life-extended bispecific T-cell engager that redirects T cells to specifically kill 6 DLL3-expressing tumor cells. In biologically relevant orthotopic and patient-derived xenograft 7 SCLC disease models, AMG 757 promoted significant tumor regression and complete antitumor 8 responses against established tumors. The antitumor effect of AMG 757 is linked to its ability to 9 promote intratumoral infiltration of activated T cells and facilitate T-cell mediated killing of DLL3- 10 expressing SCLC tumors. This, together with its acceptable nonclinical safety profile, suggest 11 that AMG 757 may be a promising novel option for SCLC therapy. AMG 757 is currently under 12 evaluation in a phase 1 clinical study (NCT03319940) for patients with SCLC. 13 Word count: 142/150 14 4 Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on November 17, 2020; DOI: 10.1158/1078-0432.CCR-20-2845 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 Introduction 2 Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor prone to early 3 metastasis, accounting for 10%–15% of all lung cancers (1-3) and associated with poor 5-year 4 survival (4). Disease relapse and resistance to therapy are common following an initial response 5 to etoposide and platinum-based chemotherapy with or without radiation therapy (5). Immune 6 checkpoint blockade has increased overall survival (OS) in SCLC despite relatively modest 7 response rates (6-9). The anti-programmed cell death-1 (anti-PD-1) antibodies nivolumab and 8 pembrolizumab received accelerated approval in the United States for the treatment of 9 metastatic SCLC with progression on or after platinum-based chemotherapy and at least one 10 other line of therapy (10,11); however, subsequent studies did not confirm increased OS 11 (12,13). The promise of targeted therapies has also not yet been realized in SCLC; a DLL3- 12 targeted antibody drug conjugate with early evidence of clinical activity demonstrated no benefit 13 in a subsequent phase 3 trial (14). Therapeutic agents with different mechanisms of action are 14 still urgently needed for patients with SCLC. 15 Bispecific T-cell engager (BiTE®) molecules are a clinically validated therapeutic modality that 16 redirect a patient’s T cells to kill tumor cells (15). Blinatumomab, the first BiTE® molecule in 17 clinical development, is approved for the treatment of relapsed/refractory B-cell precursor acute 18 lymphoblastic leukemia (16-18) and also demonstrates efficacy in non-Hodgkin lymphoma (19- 19 21). The BiTE® molecule AMG 420, which targets BCMA, demonstrated a 70% response rate in 20 multiple myeloma with 50% minimal residual disease-negative complete responses at the 21 maximum tolerated dose in a phase 1 study (22). In solid tumors, therapeutic index has been a 22 major challenge for the successful development of T cell bispecific antibodies (23,24). 23 Development of AMG 110 (MT110), which targets EpCAM, was discontinued due to on-target, 24 dose-limiting toxicity in the liver and gastrointestinal tract (24). The clinical activity of the CEA- 5 Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on November 17, 2020; DOI: 10.1158/1078-0432.CCR-20-2845 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 targeting T cell bispecific antibody, cibisatamab, is also associated with dose-limiting on-target 2 toxicity in gastrointestinal tissues (23). These data highlight the need to identify therapeutic 3 targets with tumor-specific or tumor-selective expression profiles (23,24). 4 To identify potential BiTE® molecule targets in SCLC, we profiled predicted cell surface proteins 5 for differential expression in a panel of SCLC tumors versus an array of normal tissues and 6 identified the Notch ligand, delta-like ligand 3 (DLL3). DLL3 is expressed during embryonic 7 development (25-28), and together with achaete-scute complex homologue 1, a transcription 8 factor that regulates DLL3 expression, is required for neuroendocrine differentiation and SCLC 9 tumorigenesis (29-31). We generated BiTE® molecules targeting DLL3 to explore T cell- 10 redirected lysis against SCLC tumors.
Load more

Recommended publications
  • Updates on the Role of Molecular Alterations and NOTCH Signalling in the Development of Neuroendocrine Neoplasms
    Journal of Clinical Medicine Review Updates on the Role of Molecular Alterations and NOTCH Signalling in the Development of Neuroendocrine Neoplasms 1,2, 1, 3, 4 Claudia von Arx y , Monica Capozzi y, Elena López-Jiménez y, Alessandro Ottaiano , Fabiana Tatangelo 5 , Annabella Di Mauro 5, Guglielmo Nasti 4, Maria Lina Tornesello 6,* and Salvatore Tafuto 1,* On behalf of ENETs (European NeuroEndocrine Tumor Society) Center of Excellence of Naples, Italy 1 Department of Abdominal Oncology, Istituto Nazionale Tumori, IRCCS Fondazione “G. Pascale”, 80131 Naples, Italy 2 Department of Surgery and Cancer, Imperial College London, London W12 0HS, UK 3 Cancer Cell Metabolism Group. Centre for Haematology, Immunology and Inflammation Department, Imperial College London, London W12 0HS, UK 4 SSD Innovative Therapies for Abdominal Metastases—Department of Abdominal Oncology, Istituto Nazionale Tumori, IRCCS—Fondazione “G. Pascale”, 80131 Naples, Italy 5 Department of Pathology, Istituto Nazionale Tumori, IRCCS—Fondazione “G. Pascale”, 80131 Naples, Italy 6 Unit of Molecular Biology and Viral Oncology, Department of Research, Istituto Nazionale Tumori IRCCS Fondazione Pascale, 80131 Naples, Italy * Correspondence: [email protected] (M.L.T.); [email protected] (S.T.) These authors contributed to this paper equally. y Received: 10 July 2019; Accepted: 20 August 2019; Published: 22 August 2019 Abstract: Neuroendocrine neoplasms (NENs) comprise a heterogeneous group of rare malignancies, mainly originating from hormone-secreting cells, which are widespread in human tissues. The identification of mutations in ATRX/DAXX genes in sporadic NENs, as well as the high burden of mutations scattered throughout the multiple endocrine neoplasia type 1 (MEN-1) gene in both sporadic and inherited syndromes, provided new insights into the molecular biology of tumour development.
    [Show full text]
  • Delta-Like Protein 3 Prevalence in Small Cell Lung Cancer and DLL3 (SP347) Assay Characteristics
    EARLY ONLINE RELEASE Note: This article was posted on the Archives Web site as an Early Online Release. Early Online Release articles have been peer reviewed, copyedited, and reviewed by the authors. Additional changes or corrections may appear in these articles when they appear in a future print issue of the Archives. Early Online Release articles are citable by using the Digital Object Identifier (DOI), a unique number given to every article. The DOI will typically appear at the end of the abstract. The DOI for this manuscript is doi: 10.5858/arpa.2018-0497-OA The final published version of this manuscript will replace the Early Online Release version at the above DOI once it is available. © 2019 College of American Pathologists Original Article Delta-like Protein 3 Prevalence in Small Cell Lung Cancer and DLL3 (SP347) Assay Characteristics Richard S. P. Huang, MD; Burton F. Holmes, PhD; Courtney Powell; Raji V. Marati, PhD; Dusty Tyree, MS; Brittany Admire, PhD; Ashley Streator; Amy E. Hanlon Newell, PhD; Javier Perez, PhD; Deepa Dalvi; Ehab A. ElGabry, MD Context.—Delta-like protein 3 (DLL3) is a protein that is Results.—Cytoplasmic and/or membranous staining was implicated in the Notch pathway. observed in 1040 of 1362 specimens of small cell lung Objective.—To present data on DLL3 prevalence in cancer (76.4%). Homogenous and/or heterogeneous and small cell lung cancer and staining characteristics of the partial and/or circumferential granular staining with varied VENTANA DLL3 (SP347) Assay. In addition, the assay’s immunoreactivity with other neoplastic and nonneoplastic intensities was noted.
    [Show full text]
  • And DLL4-Mediated Notch Signaling Is Essential for Adult Pancreatic Islet Homeostasis
    Diabetes Volume 69, May 2020 915 DLL1- and DLL4-Mediated Notch Signaling Is Essential for Adult Pancreatic Islet Homeostasis Marina Rubey,1,2 Nirav Florian Chhabra,1,2 Daniel Gradinger,1,2 Adrián Sanz-Moreno,1 Heiko Lickert,2,3,4 Gerhard K.H. Przemeck,1,2 and Martin Hrabe de Angelis1,2,5 Diabetes 2020;69:915–926 | https://doi.org/10.2337/db19-0795 Genes of the Notch signaling pathway are expressed in with type 2 diabetes (3), sparking investigation into their different cell types and organs at different time points roles in glucose metabolism. The highly conserved D/N during embryonic development and adulthood. The Notch signaling pathway is crucial for embryonic development ligand Delta-like 1 (DLL1) controls the decision between in a wide range of different tissues (4). Although Notch ac- endocrine and exocrine fates of multipotent progenitors in tivity is required during pancreatic development (5), some the developing pancreas, and loss of Dll1 leads to pre- D/N components have also been reported to be active mature endocrine differentiation. However, the role of during adulthood. D/N signaling mediates cell-cycle regu- Delta-Notch signaling in adult tissue homeostasis is not lation via transmembrane-bound ligands (DLL1, DLL3, DLL4, ISLET STUDIES well understood. Here, we describe the spatial expression JAGGED1, and JAGGED2) and receptors (NOTCH1–4). pattern of Notch pathway components in adult murine Studies have shown that DLL1 and DLL4 regulate tissue pancreatic islets and show that DLL1 and DLL4 are renewal and maintain intestinal progenitor cells (6). Fur- specifically expressed in b-cells, whereas JAGGED1 is thermore, NOTCH/NEUROG3 signaling is active in adult expressed in a-cells.
    [Show full text]
  • Examining the Role of Deltalike3 in Notch Signaling During Vertebrate Segmentation
    Examining the role of Deltalike3 in Notch Signaling during Vertebrate Segmentation A Senior Honors Thesis Presented in Partial Fulfillment of the Requirements for graduation with distinction in Molecular Genetics in the undergraduate colleges of The Ohio State University by Meaghan Ebetino The Ohio State University June 2008 Project Advisor: Dr. Susan Cole, Department of Molecular Genetics 2 Table of Contents I. Introduction p. 3-22 II. Results p. 22-34 III. Discussion p. 35-39 IV. Materials and Methods p. 39-42 V. References p. 43-44 3 I. Introduction Vertebrae segmentation is an embryological process regulated in part by the Notch signaling pathway. The unperturbed temporal and spatial activities of the genes involved in the Notch signaling pathway are responsible for proper skeletal phenotypes of vertebrates. The activity of Deltalike3 (Dll3), a Notch family member has been suggested to be important in both the clock and patterning activities of the Notch signaling pathway. However, the importance of Dll3 in the clock or patterning activities of the Notch signaling for proper segmentation events to occur has not been examined. Loss of Deltalike3 expression or activity in mice results in severe vertebral abnormalities, which resemble the phenotype of mice that lack the gene Lunatic fringe (Lfng), proposed to be an inhibitor of Notch. Despite the phenotypic evidence suggesting that Dll3 is an inhibitor of Notch like Lfng, there is other conflicting data suggesting that Dll3 may act either as an inhibitor or activator of Notch. My project intends to examine the role of Dll3 as an inhibitor or activator of Notch, to determine whether the Dll3 has a more important role in the clock or patterning activities of Notch signaling, and to analyze the possibility for modifier effects between Dll3 and other Notch family members.
    [Show full text]
  • Comparative Transcriptomics Reveals Similarities and Differences
    Seifert et al. BMC Cancer (2015) 15:952 DOI 10.1186/s12885-015-1939-9 RESEARCH ARTICLE Open Access Comparative transcriptomics reveals similarities and differences between astrocytoma grades Michael Seifert1,2,5*, Martin Garbe1, Betty Friedrich1,3, Michel Mittelbronn4 and Barbara Klink5,6,7 Abstract Background: Astrocytomas are the most common primary brain tumors distinguished into four histological grades. Molecular analyses of individual astrocytoma grades have revealed detailed insights into genetic, transcriptomic and epigenetic alterations. This provides an excellent basis to identify similarities and differences between astrocytoma grades. Methods: We utilized public omics data of all four astrocytoma grades focusing on pilocytic astrocytomas (PA I), diffuse astrocytomas (AS II), anaplastic astrocytomas (AS III) and glioblastomas (GBM IV) to identify similarities and differences using well-established bioinformatics and systems biology approaches. We further validated the expression and localization of Ang2 involved in angiogenesis using immunohistochemistry. Results: Our analyses show similarities and differences between astrocytoma grades at the level of individual genes, signaling pathways and regulatory networks. We identified many differentially expressed genes that were either exclusively observed in a specific astrocytoma grade or commonly affected in specific subsets of astrocytoma grades in comparison to normal brain. Further, the number of differentially expressed genes generally increased with the astrocytoma grade with one major exception. The cytokine receptor pathway showed nearly the same number of differentially expressed genes in PA I and GBM IV and was further characterized by a significant overlap of commonly altered genes and an exclusive enrichment of overexpressed cancer genes in GBM IV. Additional analyses revealed a strong exclusive overexpression of CX3CL1 (fractalkine) and its receptor CX3CR1 in PA I possibly contributing to the absence of invasive growth.
    [Show full text]
  • Mouse Dll3: a Novel Divergent Delta Gene Which May Complement the Function of Other Delta Homologues During Early Pattern Formation in the Mouse Embryo
    Development 124, 3065-3076 (1997) 3065 Printed in Great Britain © The Company of Biologists Limited 1997 DEV4879 Mouse Dll3: a novel divergent Delta gene which may complement the function of other Delta homologues during early pattern formation in the mouse embryo Sally L. Dunwoodie, Domingos Henrique, Stephen M. Harrison and Rosa S. P. Beddington Department of Mammalian Development, National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, UK *Author for correspondence (e-mail: [email protected]) SUMMARY Mouse delta-like 3 (Dll3), a novel vertebrate homologue of tion of tissue from the primitive streak and tailbud. A the Drosophila gene Delta was isolated by a subtracted careful comparison of Dll3 and Dll1 expression by double library screen. In Drosphila, the Delta/Notch signalling RNA in situ hybridisation demonstrates that these genes pathway functions in many situations in both embryonic have distinct patterns of expression, but implies that and adult life where cell fate specification occurs. In together they operate in many of the same processes. We addition, a patterning role has been described in the estab- postulate that during somitogenesis Dll3 and Dll1 coordi- lishment of the dorsoventral compartment boundary in the nate in establishing the intersomitic boundaries. We wing imaginal disc. Dll3 is the most divergent Delta confirm that, during neurogenesis in the spinal cord, Dll1 homologue identified to date. We confirm that Dll3 can and Dll3 are expressed by postmitotic cells and suggest that inhibit primary neurogenesis when ectopically expressed in expression is sequential such that cells express Dll1 first Xenopus, suggesting that it can activate the Notch receptor followed by Dll3.
    [Show full text]
  • POGLUT1, the Putative Effector Gene Driven by Rs2293370 in Primary
    www.nature.com/scientificreports OPEN POGLUT1, the putative efector gene driven by rs2293370 in primary biliary cholangitis susceptibility Received: 6 June 2018 Accepted: 13 November 2018 locus chromosome 3q13.33 Published: xx xx xxxx Yuki Hitomi 1, Kazuko Ueno2,3, Yosuke Kawai1, Nao Nishida4, Kaname Kojima2,3, Minae Kawashima5, Yoshihiro Aiba6, Hitomi Nakamura6, Hiroshi Kouno7, Hirotaka Kouno7, Hajime Ohta7, Kazuhiro Sugi7, Toshiki Nikami7, Tsutomu Yamashita7, Shinji Katsushima 7, Toshiki Komeda7, Keisuke Ario7, Atsushi Naganuma7, Masaaki Shimada7, Noboru Hirashima7, Kaname Yoshizawa7, Fujio Makita7, Kiyoshi Furuta7, Masahiro Kikuchi7, Noriaki Naeshiro7, Hironao Takahashi7, Yutaka Mano7, Haruhiro Yamashita7, Kouki Matsushita7, Seiji Tsunematsu7, Iwao Yabuuchi7, Hideo Nishimura7, Yusuke Shimada7, Kazuhiko Yamauchi7, Tatsuji Komatsu7, Rie Sugimoto7, Hironori Sakai7, Eiji Mita7, Masaharu Koda7, Yoko Nakamura7, Hiroshi Kamitsukasa7, Takeaki Sato7, Makoto Nakamuta7, Naohiko Masaki 7, Hajime Takikawa8, Atsushi Tanaka 8, Hiromasa Ohira9, Mikio Zeniya10, Masanori Abe11, Shuichi Kaneko12, Masao Honda12, Kuniaki Arai12, Teruko Arinaga-Hino13, Etsuko Hashimoto14, Makiko Taniai14, Takeji Umemura 15, Satoru Joshita 15, Kazuhiko Nakao16, Tatsuki Ichikawa16, Hidetaka Shibata16, Akinobu Takaki17, Satoshi Yamagiwa18, Masataka Seike19, Shotaro Sakisaka20, Yasuaki Takeyama 20, Masaru Harada21, Michio Senju21, Osamu Yokosuka22, Tatsuo Kanda 22, Yoshiyuki Ueno 23, Hirotoshi Ebinuma24, Takashi Himoto25, Kazumoto Murata4, Shinji Shimoda26, Shinya Nagaoka6, Seigo Abiru6, Atsumasa Komori6,27, Kiyoshi Migita6,27, Masahiro Ito6,27, Hiroshi Yatsuhashi6,27, Yoshihiko Maehara28, Shinji Uemoto29, Norihiro Kokudo30, Masao Nagasaki2,3,31, Katsushi Tokunaga1 & Minoru Nakamura6,7,27,32 Primary biliary cholangitis (PBC) is a chronic and cholestatic autoimmune liver disease caused by the destruction of intrahepatic small bile ducts. Our previous genome-wide association study (GWAS) identifed six susceptibility loci for PBC.
    [Show full text]
  • Prognostic Significance of Notch Ligands in Patients with Non‑Small Cell Lung Cancer
    506 ONCOLOGY LETTERS 13: 506-510, 2017 Prognostic significance of Notch ligands in patients with non‑small cell lung cancer 1 2 JOANNA PANCEWICZ-WOJTKIEWICZ , ANDRZEJ ELJASZEWICZ , 3 1 3 OKSANA KOWALCZUK , WIESLAWA NIKLINSKA , RADOSLAW CHARKIEWICZ , 4 1 2 MIROSLAW KOZŁOWSKI , AGNIESZKA MIASKO and MARCIN MONIUSZKO Departments of 1Histology and Embryology, 2Regenerative Medicine and Immune Regulation, 3Clinical Molecular Biology and 4Thoracic Surgery, Medical University of Bialystok, 15-269 Bialystok, Poland Received June 14, 2016; Accepted September 29, 2016 DOI: 10.3892/ol.2016.5420 Abstract. The Notch signaling pathway is deregulated in cancer patients are diagnosed with non-small-cell lung cancer numerous solid types of cancer including non-small cell (NSCLC) (3). Currently, lung cancer therapy is mainly based lung cancer (NSCLC). However, the profile of Notch ligand on Tumor-Node-Metastasis (TNM) disease staging and expression remains unclear. Therefore, the present study tumor histological classification. However, despite progress aimed to determine the profile of Notch ligands in NSCLC in surgical techniques, chemotherapy and radiotherapy, the patients and to investigate whether quantitative assessment 5-year survival rate of patients with lung cancer remains low of Notch ligand expression may have prognostic significance (~16%) (4,5). Therefore, there is a continuous need to identify in NSCLC patients. The study was performed in 61 pairs of specific and sensitive biomarkers that may improve cancer tumor and matched unaffected lung tissue specimens obtained patient management. Such markers should allow prediction from patients with various stages of NSCLC, which were and prognostication of patient survival, disease free survival analyzed by reverse transcription-polymerase chain reac- or treatment response (6).
    [Show full text]
  • NOTCH2 Participates in Jagged1-Induced Osteogenic Differentiation in Human Periodontal Ligament Cells
    www.nature.com/scientificreports OPEN NOTCH2 participates in Jagged1‑induced osteogenic diferentiation in human periodontal ligament cells Jeeranan Manokawinchoke1, Piyamas Sumrejkanchanakij1, Lawan Boonprakong2, Prasit Pavasant1, Hiroshi Egusa3 & Thanaphum Osathanon1,2,4* Jagged1 activates Notch signaling and subsequently promotes osteogenic diferentiation in human periodontal ligament cells (hPDLs). The present study investigated the participation of the Notch receptor, NOTCH2, in the Jagged1‑induced osteogenic diferentiation in hPDLs. NOTCH2 and NOTCH4 mRNA expression levels increased during hPDL osteogenic diferentiation. However, the endogenous NOTCH2 expression levels were markedly higher compared with NOTCH4. NOTCH2 expression knockdown using shRNA in hPDLs did not dramatically alter their proliferation or osteogenic diferentiation compared with the shRNA control. After seeding on Jagged1‑immobilized surfaces and maintaining the hPDLs in osteogenic medium, HES1 and HEY1 mRNA levels were markedly reduced in the shNOTCH2‑transduced cells compared with the shControl group. Further, shNOTCH2‑transduced cells exhibited less alkaline phosphatase enzymatic activity and in vitro mineralization than the shControl cells when exposed to Jagged1. MSX2 and COL1A1 mRNA expression after Jagged1 activation were reduced in shNOTCH2-transduced cells. Endogenous Notch signaling inhibition using a γ‑secretase inhibitor (DAPT) attenuated mineralization in hPDLs. DAPT treatment signifcantly promoted TWIST1, but decreased ALP, mRNA expression, compared
    [Show full text]
  • A Bispecific DLL3/CD3 Igg-Like T-Cell Antibody Induces Anti-Tumor Responses in Small Cell Lung Cancer
    Author Manuscript Published OnlineFirst on June 18, 2020; DOI: 10.1158/1078-0432.CCR-20-0926 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Title Page Title: A Bispecific DLL3/CD3 IgG-like T-cell Antibody induces anti-tumor responses in Small Cell Lung Cancer Running title: A Novel DLL3-targeted IgG-like T-cell Engager Authors and affiliations: Susanne Hipp1, Vladimir Voynov2, Barbara Drobits-Handl3, Craig Giragossian2, Francesca Trapani4, Andrew E. Nixon2, Justin M. Scheer2, and Paul J. Adam5 1 Boehringer Ingelheim Pharmaceuticals, Inc., Cancer Immunology & Immune Modulation, Ridgefield, CT, USA 2 Boehringer Ingelheim Pharmaceuticals, Inc., Biotherapeutics Discovery, Ridgefield, CT, USA 3 Boehringer Ingelheim RCV, GmbH & Co KG., Cancer Pharmacology and Disease Positioning, Vienna, Austria 4 Boehringer Ingelheim RCV, GmbH & Co KG., Oncology Translational Science, Vienna, Austria 5 Boehringer Ingelheim RCV, GmbH & Co KG., Cancer Immunology & Immune Modulation, Vienna, Austria Corresponding author: Susanne Hipp 900 Ridgebury Rd./P.O. Box 368 Ridgefield, CT06877-0368, USA Phone: 203-798-4567 Email: [email protected] Conflict of interest disclosure: All authors are employees of Boehringer Ingelheim affiliates. Boehringer Ingelheim has filed patent applications on aspects of this work. 1 Downloaded from clincancerres.aacrjournals.org on September 28, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on June 18, 2020; DOI: 10.1158/1078-0432.CCR-20-0926 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Translational relevance Small cell lung cancer (SCLC) is the most lethal and aggressive subtype of lung carcinoma characterized by a high relapse rate to chemotherapy in a majority of patients.
    [Show full text]
  • Blockade of Specific NOTCH Ligands: a New Promising Approach in Cancer Therapy
    VIEWS IN THE SPOTLIGHT Blockade of Specifi c NOTCH Ligands: A New Promising Approach in Cancer Therapy Anaïs Briot 1 and M. Luisa Iruela-Arispe 1,2,3 Summary: The signaling specifi city conveyed by distinct combination of NOTCH receptors/ligands has remained elusive. In this issue of Cancer Discovery , through the development of ligand-specifi c NOTCH inhibitors, Kangsa- maksin and colleagues uncovered unique signaling outcomes downstream of DLL- and JAG-receptor activation and demonstrated their effects in the suppression of tumor angiogenesis. Cancer Discov; 5(2); 112–4. ©2015 AACR. See related article by Kangsamaksin et al., p. 182 (1). The vasculature of tumors arises from two processes: (i) plex composed of RBPJK /CSL and Mastermind-like proteins co-option of existent vessels present within the tissue that (MAML) to induce the transcription of target genes. harbors the tumor and (ii) growth of new vessels, also referred Activation of the NOTCH pathway has been shown to to as angiogenesis. As an important hallmark of cancer, regulate multiple genes in a cell- and context-dependent angiogenesis has been the successful target of therapeutic manner ( 2 ). Its critical role in development and homeostasis approaches aiming at depriving tumor cells of nutrients and is highlighted by the broad number of anomalies and disor- oxygen. During angiogenesis, vascular sprouts are initiated ders that arise once the pathway goes awry. These disorders by the departure of endothelial cells (tip cells) from the vessel include vascular anomalies (CADASIL), cardiac malforma- core (stalk cells). Tip endothelial cells are morphologically, tions (Alagille syndrome), and liver dysfunctions (Alagille molecularly, and functionally distinct from stalk cells, and syndrome).
    [Show full text]
  • A Comprehensive Bioinformatics Analysis of Notch Pathways in Bladder Cancer
    cancers Article A Comprehensive Bioinformatics Analysis of Notch Pathways in Bladder Cancer Chuan Zhang 1,2 , Mandy Berndt-Paetz 1 and Jochen Neuhaus 1,* 1 Department of Urology, University of Leipzig, 04109 Leipzig, Germany; [email protected] (C.Z.); [email protected] (M.B.-P.) 2 Department of Urology, Chengdu Fifth People’s Hospital Affiliated to the Chengdu University of Traditional Chinese Medicine, Chengdu 611130, China * Correspondence: [email protected]; Tel.: +49-341-971-7688 Simple Summary: The Notch pathway is important in embryology and numerous tumor diseases. However, its role in bladder cancer (BCa) has not been deeply investigated thus far. Gene expression data are available for BCa, and bioinformatics analysis can provide insights into a possible role of the Notch pathway in BCa development and prognosis. Using this information can help in better understanding the origin of BCa, finding novel biomarkers for prediction of disease progression, and potentially opening new avenues to improved treatment. Our analysis identified the Notch receptors NOTCH2/3 and their ligand DLL4 as potential drivers of BCa by direct interaction with basic cell functions and indirect by modulating the immune response. Abstract: Background: A hallmark of Notch signaling is its variable role in tumor biology, ranging from tumor-suppressive to oncogenic effects. Until now, the mechanisms and functions of Notch pathways in bladder cancer (BCa) are still unclear. Methods: We used publicly available data from the GTEx and TCGA-BLCA databases to explore the role of the canonical Notch pathways Citation: Zhang, C.; Berndt-Paetz, in BCa on the basis of the RNA expression levels of Notch receptors, ligands, and downstream M.; Neuhaus, J.
    [Show full text]